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Abstract
Introduction
•Opioid addiction plagues our country. Short term opioid use has 
been shown to be beneficial for patients, but many of those 
patients continue to receive opioids for years (Lembke, 
Humphreys, & Newmark, 2016).  The addiction ranges from 
patients receiving chronic opioid prescriptions to those buying 
them on the street and abusing. This epidemic has become a 
significant public health problem.  There is increased morbidity 
and mortality associated with opioid use, as well as an increase in 
the spread of HIV and hepatitis (Nielsen et al., 2016). 
•Opioid maintenance therapy has been shown to reduce the use of 
abused opioids.  Patients are able to return to normal social 
functioning and decrease their criminal activity. This also 
decreases the transmission of infectious diseases such as HIV and 
hepatitis (Nunes et al.,2015).
•The Substance Abuse and Mental Health Services Administration 
endorses three medications to use for opioid maintenance 
treatment: buprenorphine, methadone, and naltrexone. While all 
three have their benefits and their challenges, this researcher has 
reviewed the current literature to make an informed decision as to 
which is the best treatment option of the three (buprenorphine, 




Applicability to Clinical Practice Acknowledgements
Discussion
Methadone has been used the longest for opioid maintenance 
treatment.  It is tried and true, but patient preference is poor.  
Patients are limited by location of methadone clinics and the 
daily dosages. 
Buprenorphine is a newer medication, but has shown similar 
retention and efficacy to methadone.  Providers are still limited 
by certification, but not location so are more abundant.  Dosage 
is not daily.
Naltrexone is the newest treatment of the three.  It is little better 
than placebo as an oral medication, but has shown promise in 
extended release and implantable forms.  These forms allow for 
at least a month of treatment per dose and have also been used 
to discontinue the use of buprenorphine.  There is also no 
limitations to prescribers.
Naltrexone allows for more patient autonomy and reduces the time 
and travel barriers seen with buprenorphine and methadone.  It 
can bring opioid treatment to rural areas that otherwise were 
without. 
Opioid dependence plagues the United States with millions of 
people suffering from the effects.  Throughout recent years, 
there has been a surge in research in treatment options for 
patients suffering from opioid dependence.  Three medications 
have stood out: methadone, buprenorphine, and naltrexone. The 
purpose of this study was to investigate the three and decipher 
which provides the best outcomes for patients.   Research was 
conducted by reviewing literature via PubMed, PsychInfo and 
Cochrane. A review of the literature found that methadone has 
been used the longest and has been shown to be efficacious, but 
can be severely limiting for patients due to lack of clinics and 
the need for daily dosings.  As a result, buprenorphine was 
developed as an alternative medication with similar efficacy and 
retention rates to combat the daily dosages and provide a more 
readily available medication.  Unfortunately buprenorphine also 
has geographical limitations. Naltrexone is the newest 
medication added to the mix.  Orally, it has poor retention, but 
an extended release form has been developed that is showing 
promise.  There are no geographical limitations associated with 
naltrexone and the extended release form allows for only 
monthly injections.  Going forward with opioid treatment, 
medications like naltrexone and those that are more readily 
available will become more widely used for treatment as patient 
preference is pointing towards medications that are not limited 
by geography or frequent dosing.
• Of the three pharmacological opioid maintenance therapy 
options endorsed by the Substance Abuse and Mental Health 
Services administration: methadone, buprenorphine, and 
naltrexone, which has the best outcomes for patients taking into 
account efficacy, retention rate, availability, and patient 
preference?
A review of the literature provided the following main points:
- Methadone
- Schukit (2016) states that methadone is superior to placebo 
for both managing withdrawal and retention in treatment 
plans.
- Per Uebelaker et al. (2015), patients do not feel that 
methadone is the best treatment option, noting barriers such 
as location and time.  They do not feel they are drug free. 
- Buprenorphine
- Nielsen et al. (2016) found that buprenorphine and 
methadone have similar retention and efficacy, but that 
buprenorphine may be safer as it has less sedation and 
respiratory depression.
- Lobmaier et al. (2010) discussed the abuse potential of 
buprenorphine and as such recommend the combination of 
buprenorphine and naloxone. 
- Rosenthal (2013) researched an implantable form of 
buprenorphine that was found to be three times as effective 
as placebo and similar to sublingual buprenorphine.
- Naltrexone
- Lobmaier et al. (2010) found that oral naltrexone is similar 
only to placebo except in highly motivated individuals for 
treatment. 
- Nunes et al. (2015) researched an extended release form 
that has significantly better outcomes than placebo and 
oral.  At 24 weeks, 80% of patients had drug free urines as 
compared to 15% of patient on oral. 
- Dakwar and Kleber (2015) proposed that the injectable 
naltrexone can be used to discontinue buprenorphine.  For 
the six patients in the study, only one injection was needed 
to discontinue use. 
First and foremost, there must be a change in how opioids are 
prescribed by providers.  CDC came out with revised guidelines 
in March of 2016 for primary care providers addressing when to 
prescribe, how to select, and how to assess and address risk with 
patients.
Treatment options must also change.  Patient preference affects 
treatment and preference has been towards long acting
I would like to thank UND faculty for their help and 
encouragement during the process of this project, in particular my 
advisor Russ Kauffman.  Thank yous also go out to both Marilyn 
Klug for her guidance with the studies chosen and to Erik 
Christenson for the insight he provided from a pharmacist’s point 
of view.  To my peer group, I thank Savannah Prodzinski, Aggie 
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Statement of the Problem
• With the increasing opioid addiction epidemic in our country, 
effective treatment options are necessary to reverse the trend. 
Many different pharmacological options are available for opioid 
maintenance therapy, but research is needed to show which 
medication has the best efficacy taking into factor such aspects as 
relapse rates and patient compliance. 
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the use of an oral,
long-acting opioid
Restriction Patient must 
be opioid-free
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medications that require little travel and little time                           
constraints.  Drugs like methadone need to be more 
readily available and have more effective delivery
methods.
A third shift must be in attitudes towards opioid misuse.  It 
is a chronic disease similar to hypertension and 
diabetes.  Patients and providers alike must realize 
that like any other chronic disease, treatment may be 
on going. 
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